ReviewClinical pharmacokinetics2017
Clinical Pharmacokinetics of Vemurafenib.
Review in Clinical pharmacokinetics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04943198 (Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis), which is not on this map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Sex and gender influence on adverse events for melanoma patients: a comprehensive review and meta-analysis.British journal of cancer · 2026Pooled it
- Pooled it
- Molecular therapy for papillary craniopharyngioma: a multi-institutional analysis of practice patterns across the RAPID Consortium.Journal of neuro-oncology · 2026Article
- Precision-guided therapy in dialysis-dependent classic hairy cell leukemia: a case report.Frontiers in oncology · 2026Article
- Very low-dose vemurafenib maintenance for cardiac Erdheim Chester disease.Blood research · 2025Article
- Efficacy of innovative systemic treatments in combination with radiotherapy for bone metastases: a GEMO (the European Study Group of Bone Metastases) state of the art.Cancer metastasis reviews · 2025Review
- Sol-moiety: Discovery of a water-soluble prodrug technology for enhanced oral bioavailability of insoluble therapeutics.Nature communications · 2024Article
- Novel drug resistance mechanisms and drug targets in BRAF-mutated peritoneal metastasis from colorectal cancer.Journal of translational medicine · 2024Article
- Integration of Pan-Cancer Cell Line and Single-Cell Transcriptomic Profiles Enables Inference of Therapeutic Vulnerabilities in Heterogeneous Tumors.Cancer research · 2024Article
- Sex differences in patients with Non-Small Cell Lung Cancer harboring driver fusions treated with tyrosine kinase inhibitors: a systematic review.Therapeutic advances in medical oncology · 2024Review
- Inferring therapeutic vulnerability within tumors through integration of pan-cancer cell line and single-cell transcriptomic profiles.bioRxiv : the preprint server for biology · 2023Article
- Vemurafenib inhibits necroptosis in normal and pathological conditions as a RIPK1 antagonist.Cell death & disease · 2023Article
- Review
- In Silico Studies of Novel Vemurafenib Derivatives as BRAF Kinase Inhibitors.Molecules (Basel, Switzerland) · 2023Article
- Vemurafenib improves muscle histopathology in a mouse model of LAMA2-related congenital muscular dystrophy.Disease models & mechanisms · 2023Article
- Therapeutic Monitoring of Orally Administered, Small-Molecule Anticancer Medications with Tumor-Specific Cellular Protein Targets in Peripheral Fluid Spaces-A Review.Pharmaceutics · 2023Review
- Mixture Cure Models in Oncology: A Tutorial and Practical Guidance.PharmacoEconomics - open · 2021Article
- Assessing OATP1B1- and OATP1B3-Mediated Drug-Drug Interaction Potential of Vemurafenib Using R-Value and Physiologically-Based Pharmacokinetic Models.Journal of pharmaceutical sciences · 2021Article
- Optimized low-dose combinatorial drug treatment boosts selectivity and efficacy of colorectal carcinoma treatment.Molecular oncology · 2020Article
- Relationship between vemurafenib plasma concentrations and survival outcomes in patients with advanced melanoma.Cancer chemotherapy and pharmacology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vemurafenib is an orally administered small-molecule inhibitor of the oncogenic BRAF kinase that is indicated for the treatment of patients with unresectable or metastatic melanoma harbouring BRAF
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.